Ovarian Neoplasms

Oncology
27
Pipeline Programs
14
Companies
50
Clinical Trials
7 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
9
0
13
1
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
267%
Monoclonal Antibody
133%
+ 26 programs with unclassified modality

On Market (2)

Approved therapies currently available

Regeneron
EYLEAApproved
aflibercept
Regeneron
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2011
Regeneron
EYLEA HDApproved
aflibercept
Regeneron
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2023

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
2 programs
1
1
1
afliberceptPhase 2/3
AfliberceptPhase 2
M&
Merck & Co.RAHWAY, NJ
3 programs
1
1
Sacituzumab tirumotecanPhase 35 trials
Pegylated Liposomal DoxorubicinPhase 25 trials
CaelyxN/A1 trial
Active Trials
NCT00743431Completed224Est. Dec 2008
NCT01492881Withdrawn0Est. Jan 2017
NCT00604968Terminated25Est. Oct 2009
+8 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
Sofetabart MipitecanPhase 31 trial
Active Trials
NCT07213804Recruiting1,080Est. Aug 2031
Pfizer
PfizerNEW YORK, NY
5 programs
3
2
CP-547,632Phase 21 trial
SGN-15Phase 21 trial
Felmetatug VedotinPhase 1ADC1 trial
PF-07260437Phase 11 trial
SGN-ALPVPhase 11 trial
Active Trials
NCT05194072Terminated250Est. May 2025
NCT05067972Terminated30Est. Oct 2023
NCT05229900Terminated43Est. Dec 2023
+2 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
4 programs
2
2
BIBF1120Phase 21 trial
PaclitaxelPhase 21 trial
BIBF 1120Phase 11 trial
BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*minPhase 11 trial
Active Trials
NCT01329549Terminated2Est. Oct 2012
NCT01314105Completed19Est. Apr 2016
NCT00710762Completed89Est. Mar 2014
+1 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
1
AZD2281Phase 21 trial
An INternational Frontline Ovarian Cancer Real World Management StudyN/A1 trial
Prospective Identification and Validation of "BRCANess" Profile in Ovarian Epithelial CancerN/A1 trial
Active Trials
NCT04460768Completed989Est. Nov 2020
NCT02524808Unknown230Est. Jul 2016
NCT00628251Completed97Est. Sep 2018
Genentech
GenentechCA - Oceanside
2 programs
1
1
bevacizumabPhase 2Monoclonal Antibody1 trial
89Zr-MMOT0530APhase 11 trial
Active Trials
NCT01832116Completed11Est. May 2014
NCT00130520Completed40Est. May 2010
Bayer
BayerLEVERKUSEN, Germany
2 programs
1
1
SagopilonePhase 25 trials
Anetumab ravtansinePhase 1ADC5 trials
Active Trials
NCT03102320Completed173Est. Jul 2021
NCT03023722Completed18Est. Dec 2019
NCT02824042Completed63Est. Aug 2019
+7 more trials
Novartis
NovartisBASEL, Switzerland
2 programs
1
1
epothilone bPhase 21 trial
LTT462Phase 11 trial
Active Trials
NCT02711345Terminated65Est. Nov 2018
NCT00035100Completed54
Astellas
AstellasChina - Shenyang
1 program
1
OSI-211Phase 22 trials
Active Trials
NCT00046800Completed80Est. Mar 2003
NCT00046787Completed47Est. Feb 2003
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
TrabectedinPhase 21 trial
Active Trials
NCT00050414Completed147Est. Sep 2005
OD
1 program
1
doxorubicin HCL liposome; bevacizumab; carboplatinPhase 2
Kazia Therapeutics
Kazia TherapeuticsAustralia - Sydney
1 program
1
Part A: Dose Escalation of CantrixilPhase 11 trial
Active Trials
NCT02903771CompletedEst. Mar 2020
Sanofi
SanofiPARIS, France
1 program
DocetaxelN/A1 trial
Active Trials
NCT00452985Completed30Est. Nov 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Merck & Co.Pegylated Liposomal Doxorubicin
Merck & Co.Pegylated Liposomal Doxorubicin
Merck & Co.Pegylated Liposomal Doxorubicin
Merck & Co.Sacituzumab tirumotecan
Merck & Co.Sacituzumab tirumotecan
Eli Lilly and CompanySofetabart Mipitecan
Merck & Co.Sacituzumab tirumotecan
Merck & Co.Sacituzumab tirumotecan
Merck & Co.Sacituzumab tirumotecan
Merck & Co.Sacituzumab tirumotecan
Merck & Co.Sacituzumab tirumotecan
Merck & Co.Sacituzumab tirumotecan
Merck & Co.Pegylated Liposomal Doxorubicin
PfizerSGN-15
Merck & Co.Sacituzumab tirumotecan

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 9,091 patients across 50 trials

NCT00604968Merck & Co.Pegylated Liposomal Doxorubicin

Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)

Start: Feb 2007Est. completion: Oct 200925 patients
Phase 4Terminated
NCT00779285Merck & Co.Pegylated Liposomal Doxorubicin

Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)

Start: Feb 2006Est. completion: Aug 20061 patients
Phase 4Terminated
NCT00727961Merck & Co.Pegylated Liposomal Doxorubicin

A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)

Start: Nov 2004Est. completion: Jan 200858 patients
Phase 4Completed
NCT07419295Merck & Co.Sacituzumab tirumotecan

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Start: Mar 2026Est. completion: Apr 2030590 patients
Phase 3Not Yet Recruiting
NCT07318558Merck & Co.Sacituzumab tirumotecan

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Start: Feb 2026Est. completion: Feb 2033900 patients
Phase 3Recruiting
NCT07213804Eli Lilly and CompanySofetabart Mipitecan

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Start: Oct 2025Est. completion: Aug 20311,080 patients
Phase 3Recruiting
NCT06824467Merck & Co.Sacituzumab tirumotecan

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Start: Apr 2025Est. completion: Nov 2032770 patients
Phase 3Recruiting
NCT06459180Merck & Co.Sacituzumab tirumotecan

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Start: Jul 2024Est. completion: Jun 2028686 patients
Phase 3Recruiting
NCT06305754Merck & Co.Sacituzumab tirumotecan

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Start: Jun 2024Est. completion: Jun 2030520 patients
Phase 3Recruiting
NCT06356311Merck & Co.Sacituzumab tirumotecan

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Start: May 2024Est. completion: May 2027450 patients
Phase 3Active Not Recruiting
NCT06132958Merck & Co.Sacituzumab tirumotecan

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Start: Dec 2023Est. completion: Jan 2028710 patients
Phase 3Active Not Recruiting
NCT06074588Merck & Co.Sacituzumab tirumotecan

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Start: Nov 2023Est. completion: Mar 2030556 patients
Phase 3Recruiting
NCT00266799Merck & Co.Pegylated Liposomal Doxorubicin

The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)

Start: Jan 2006Est. completion: Oct 2010210 patients
Phase 3Completed
NCT00051584PfizerSGN-15

Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer

Est. completion: May 200360 patients
Phase 2Terminated
NCT07438626Merck & Co.Sacituzumab tirumotecan

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

Start: Jun 2026Est. completion: Feb 203020 patients
Phase 2Not Yet Recruiting
NCT07458113Merck & Co.Sacituzumab tirumotecan

Sac-TMT for Active TNBC Brain Metastases

Start: May 2026Est. completion: May 202920 patients
Phase 2Not Yet Recruiting
NCT03023722BayerAnetumab ravtansine

Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

Start: May 2017Est. completion: Dec 201918 patients
Phase 2Completed
NCT02610140BayerAnetumab ravtansine

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Start: Dec 2015Est. completion: Sep 2019248 patients
Phase 2Completed
NCT01492881Merck & Co.Pegylated Liposomal Doxorubicin

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Start: Apr 2012Est. completion: Jan 20170
Phase 2Withdrawn
NCT01121406Boehringer IngelheimPaclitaxel

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Start: Apr 2010Est. completion: Jun 2014110 patients
Phase 2Completed
NCT00751205BayerSagopilone

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Start: Aug 2008Est. completion: Aug 2010150 patients
Phase 2Completed
NCT00628251AstraZenecaAZD2281

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

Start: Jul 2008Est. completion: Sep 201897 patients
Phase 2Completed
NCT00496379BayerSagopilone

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

Start: Jul 2007Est. completion: Jan 201215 patients
Phase 2Terminated
NCT00598507BayerSagopilone

Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

Start: May 2007Est. completion: Jan 201335 patients
Phase 2Completed
NCT00325351BayerSagopilone

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Start: Aug 2006Est. completion: Mar 200945 patients
Phase 2Completed
NCT00350051BayerSagopilone

ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer

Start: Aug 2006Est. completion: Dec 200953 patients
Phase 2Completed
NCT00299390BayerSagopilone

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer

Start: Apr 2006Est. completion: Apr 200710 patients
Phase 2Terminated
NCT00710762Boehringer IngelheimBIBF1120

A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer

Start: Mar 2006Est. completion: Mar 201489 patients
Phase 2Completed
NCT00288249BayerSagopilone

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer

Start: Dec 2005Est. completion: Jan 200982 patients
Phase 2Completed
NCT00246688BayerSagopilone

Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer

Start: Nov 2005Est. completion: Jun 200763 patients
Phase 2Completed
NCT00160069BayerSagopilone

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer

Start: Aug 2005Est. completion: Apr 2009128 patients
Phase 2Completed
NCT00130520Genentechbevacizumab

Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

Start: Jun 2005Est. completion: May 201040 patients
Phase 2Completed
NCT00074867PfizerCP-547,632

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

Start: Oct 2003Est. completion: Sep 200429 patients
Phase 2Completed
NCT00780039Merck & Co.Pegylated Liposomal Doxorubicin

A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

Start: Oct 2003Est. completion: Sep 200758 patients
Phase 2Completed
NCT00050414Johnson & JohnsonTrabectedin

A Study of Trabectedin in Patients With Advanced Ovarian Cancer

Start: Oct 2002Est. completion: Sep 2005147 patients
Phase 2Completed
NCT00046787AstellasOSI-211

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

Start: Sep 2002Est. completion: Feb 200347 patients
Phase 2Completed
NCT00046800AstellasOSI-211

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

Start: Sep 2002Est. completion: Mar 200380 patients
Phase 2Completed
NCT00035100Novartisepothilone b

EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer

Start: Sep 200154 patients
Phase 2Completed
NCT06637423Merck & Co.Sacituzumab tirumotecan

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Start: Dec 2024Est. completion: Jul 202832 patients
Phase 1/2Recruiting
NCT00359359BayerSagopilone

A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer

Start: Jul 2006Est. completion: Aug 200926 patients
Phase 1/2Completed
NCT05229900PfizerSGN-ALPV

A Study of SGN-ALPV in Advanced Solid Tumors

Start: Apr 2022Est. completion: Dec 202343 patients
Phase 1Terminated
NCT05194072PfizerFelmetatug Vedotin

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Start: Jan 2022Est. completion: May 2025250 patients
Phase 1Terminated
NCT05067972PfizerPF-07260437

A Study of PF-07260437 in Advanced or Metastatic Solid Tumors

Start: Oct 2021Est. completion: Oct 202330 patients
Phase 1Terminated
NCT03102320BayerAnetumab ravtansine

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Start: May 2017Est. completion: Jul 2021173 patients
Phase 1Completed
NCT02903771Kazia TherapeuticsPart A: Dose Escalation of Cantrixil

Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

Start: Dec 2016Est. completion: Mar 2020
Phase 1Completed
NCT02824042BayerAnetumab ravtansine

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

Start: Sep 2016Est. completion: Aug 201963 patients
Phase 1Completed
NCT02751918BayerAnetumab ravtansine

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Start: Jun 2016Est. completion: Oct 201965 patients
Phase 1Completed
NCT02711345NovartisLTT462

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Start: Apr 2016Est. completion: Nov 201865 patients
Phase 1Terminated
NCT02696642BayerAnetumab ravtansine

Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

Start: Apr 2016Est. completion: Aug 201954 patients
Phase 1Completed
NCT02639091BayerAnetumab ravtansine

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Start: Feb 2016Est. completion: Oct 201936 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
7 actively recruiting trials targeting 9,091 patients
14 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)